Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in hematologic complete remission after multiagent therapy exhibit minimal residual disease (MRD) by reverse transcriptase–polymerase chain reaction or flow cytometry. MRD is the strongest predictor of relapse in ALL. In this...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood
Autores principales: Gökbuget, Nicola, Dombret, Hervé, Bonifacio, Massimiliano, Reichle, Albrecht, Graux, Carlos, Faul, Christoph, Diedrich, Helmut, Topp, Max S., Brüggemann, Monika, Horst, Heinz-August, Havelange, Violaine, Stieglmaier, Julia, Wessels, Hendrik, Haddad, Vincent, Benjamin, Jonathan E., Zugmaier, Gerhard, Nagorsen, Dirk, Bargou, Ralf C.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2018
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6027091/
https://ncbi.nlm.nih.gov/pubmed/29358182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-08-798322
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares